System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Annabel Maruani is an expert in Dermatology at Centre Hospitalier Universitaire de Tours (France). As of October 2026, ScienceLeadR ranks Annabel Maruani in the top 1% of experts worldwide for Congenital Abnormalities and Sexually Transmitted Diseases. Annabel Maruani has authored 423 publications, the most recent in 2026, and is an investigator in 25 clinical trials, 9 of them ongoing. SLR score: 1,436 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Annabel Maruani Centre Hospitalier Universitaire de Tours France
1 436 ScienceLeadR Reputation 1436

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Infectiology - Pediatrics - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2003 - 2026
Source: PubMed

Centre Hospitalier Universitaire de Tours

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 423

Citations

Citations: 4 930 1st author: 40 Last author: 112 Unique author: 3

Main journals

Ann Dermatol Venereol 135
Br J Dermatol 29
Acta Derm Venereol 28
J Eur Acad Dermatol Venereol 24
Presse Med 18

Best Journals

N Engl J Med 2
BMJ 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Darier disease international task force: From mechanistic insights to precision medicine.
PMID 42788401 — sexually transmitted diseases, darier disease, precision medicine		J Eur Acad Dermatol Venereol20260
Peripheral vasomotor symptoms: Expanding the phenotype of GNA11-related capillary malformations.
PMID 42755085 — sexually transmitted diseases, capillaries, mosaicism, phenotype, skin diseases, signs and symptoms		J Eur Acad Dermatol Venereol20260
A New Phototherapy Regimen Coupled with Oral Vitamin D Supplementation, for the Long-Term Control of Atopic Dermatitis: A French Multicenter, Randomized, Crossover, Pragmatic Trial.
PMID 42728529 — vitamin d, dermatitis, vitamins, phototherapy, genes, tat, therapeutics, dermatitis, atopic		Dermatol Ther (Heidelb)20260
Over-the-counter Products and Complementary Therapies in Childhood Atopic Dermatitis: a National Survey of Pharmacists.
PMID 42626974 — syphilis, dermatitis, pharmacists, therapeutics, dermatology, dermatitis, atopic, complementary therapies		Br J Dermatol20260
Pediatric Phthiriasis Palpebrarum: A French Multicentric Retrospective Study of 20 Cases.
PMID 42437072 — eyelids, retrospective studies, diagnosis, therapeutics, pediatrics, child abuse, child		J Pediatr Clin Pract20260

Clinical Studies 25

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 6 Study Director: 2

By phase:

N/A 11
Phase 2 7
Phase 3 5
Phase 2/Phase 3 2

By status:

Completed 11
Recruiting 9
Unknown 3
Active not recruiting 2

By type:

Interventional 20
Observational 5

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 3
multicentric5to9 1
multicentricup10 16

Main Topics

Ongoing Clinical Trials

9 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE AA PEDS)
2022-502700-78-00 — safety, alopecia areata, child, alopecia, pharmacokinetics		Phase 3Active not recruiting2023
Alpelisib for the treatment of lymphatic malformations associated with a PIK3CA mutation
2023-504146-60-00 — safety, therapeutics, mutation, pharmacokinetics		Phase 2/Phase 3Recruiting2024
EPIK P4 A Phase II single arm study to assess the efficacy safety and pharmacokinetics of alpelisib (BYL719) in pediatric and adult patients with PIK3CA related overgrowth spectrum (PROS)
2024-519960-42-00 — safety, pharmacokinetics		Phase 2Recruiting2025
CongenItal Naevus Cohort for Longitudinal Evaluation
NCT06828822 — skin, quality of life, parturition, melanoma, brain, neurodevelopmental disorders, therapeutics, nevus, child, neurodevelopment		N/ARecruiting2025
A 20 Week Study Assessing the Efficacy of Apremilast in Patients with EB Simplex Generalized
NCT06509984 — safety, epidermolysis bullosa simplex, epidermolysis bullosa, therapeutics, child		Phase 2Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS